Johnson & Johnson announced it will reduce its workforce and restructure.
More than 4,000 employees - approximately 4% of the company's human resources - were scheduled to be let go during the fourth quarter of 1998. Johnson & Johnson had a total work force of 94,000 before the announcement.
The workforce reductions will not take place in its pharmaceutical sales division, the company clarified. Currently, the company employs nearly 3,000 pharmaceutical sales reps.
According to reports in the Wall Street Journal, 5,800 positions will be eliminated. The majority of the layoffs will take place in its manufacturing facilities. The company also announced that it will close 36 factories.
Altogether, the decision will cost Johnson & Johnson $800 million. The move, the company said, is part of a long-term effort to improve production efficiency and centralize manufacturing functions.
Over time, the restucturing could save the company $250 to $300 million per year. Those savings could be applied to the creation of 1,700 new positions, most likely in the sales and marketing departments.
The restructuring, industry analysts predict, will have little effect on the company's pharmaceutical business. PR
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 18th 2025Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a biosimilar to Xgeva, is indicated for preventing skeletal-related events in multiple myeloma and solid tumor bone metastases.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.